Results 191 to 200 of about 270,921 (246)

Association of Ferritin Levels With Cytokine Release Syndrome in CAR T‐Cell Therapy: A Systematic Review and Meta‐Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
CAR T‐cell infusion can induce production of excessive cytokines resulting in cytokine release syndrome (CRS). Ferritin is elevated in severe CRS and both pre‐ and post‐infusion levels are associated with poor survival. ABSTRACT Background Ferritin elevation is frequently observed during cytokine release syndrome (CRS) following CAR T‐cell therapy ...
Ranjit Sah, Abhinav Bhattarai, Sangam Shah, Rachana Mehta, Sanjit Sah, Zeeshan Solangi, George P. Sorescu   +6 more
wiley   +1 more source

Transformation of T-lymphoblastic lymphoma into acute myeloid leukemia after recurrence: a case report and literature review. [PDF]

Front Oncol
Yang M, Mei W, Zhao X.
europepmc   +1 more source

A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Atypical teratoid/rhabdoid tumors (ATRTs) are aggressive pediatric brain tumors that are sensitive to proteasome inhibitors in preclinical models. We evaluated the feasibility of combining the proteasome inhibitor, bortezomib, with chemotherapy.
Wan‐Ling Ho, Ming‐Yun Hsieh, Yu‐Mei Liao, Shyh‐Shin Chiou, Her‐Shyong Shiah, Chang‐Hsu Chiang, Shiann‐Tarng Jou, Hsiu‐Ju Yen, Yi‐Yen Lee, Muh‐Lii Liang, Ting‐Chi Yeh, Yu‐Cheng Chou, Fang‐Liang Huang, Shu‐Huey Chen, Hsin‐Lun Lee, Chia‐Chun Kuo, Yi‐Shan Yang, Shu‐Mei Chen, Min‐Lan Tsai, Hsi Chang, Kevin Li‐Chun Hsieh, Chia‐Lang Fang, Chia‐Yau Chang, Jinn‐Li Wang, Chu‐Chin Chen, Joon‐Khim Loh, Pei‐Chin Lin, Tzu‐Chin Lin, Shih‐Chung Wang, Yi‐Fang Tu, Chao‐Neng Cheng, Jimmy Ming‐Jung Chuang, Huy Minh Tran, Shian‐Ying Sung, Irving Lai, Kuo‐Sheng Wu, James S. Miser, Yen‐Lin Liu, Tai‐Tong Wong   +38 more
wiley   +1 more source

Fc engineering of a fully humanized anti-CD147 monoclonal antibody enhances ADCC against T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. [PDF]

Sci Rep
Htet ZY, Pamonsupornwichit T, Sornsuwan K, Viriyaadhammaa N, Jantaree P, Yasamut U, Intasai N, Tayapiwatana C.   +7 more
europepmc   +1 more source

Target‐Specific Dermatological Adverse Event Reporting With T‐Cell–Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016–2026

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background T‐cell–engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid‐tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target‐specific dermatological adverse event reporting patterns remain poorly defined.
Saikat Mandal, Manideepa Maji, Arkadeep Dhali   +2 more
wiley   +1 more source

Daratumumab-based salvage therapy enables umbilical cord blood transplantation in multiline refractory, elderly T-lymphoblastic lymphoma: a case report. [PDF]

Front Immunol
Yang Q, Yang L, Cai P, Ji YH, Zhou JD, Qian J.   +5 more
europepmc   +1 more source

Clinical Characteristics and Prognostic Factors of Primary Bone Diffuse Large B‐Cell Lymphoma: A Retrospective Study

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Primary bone diffuse large B‐cell lymphoma (PB‐DLBCL) is a rare extranodal lymphoma with heterogeneous clinical features and survival outcomes. Although most patients respond favorably to modern immunochemotherapy, reliable baseline prognostic indicators remain insufficiently defined. Methods We retrospectively analyzed 424 patients
Zhenbo Hou, Kebing Chen, Yuling Lu, Xuejun Ma, Shengjian Zhang, Junning Cao, Qunling Zhang, Yizhen Liu   +7 more
wiley   +1 more source

Outcomes of T-cell lymphoblastic lymphoma in children and adolescents treated with Dana-Farber Cancer Institute Childhood ALL Consortium protocols. [PDF]

Front Pediatr
Gotti G, Flamand Y, Koch V, Testa S, Stevenson K, Tran TH, Michon B, Athale U, Silverman LB, Pikman Y, Place AE.   +10 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Genetic Determinants of Treatment‐Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 786-794, September 2026.
Osteonecrosis and fractures are serious corticosteroid‐induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustness of both newly identified and previously ...
Rachid Abaji, Vincent Gagné, Émilie Espagne, Nathalie Alos, Veronica Del Vecchio, Lamia Ait Said, Albert Shalmiev, Claire Fuchs, Caroline Laverdière, Jean‐Marie Leclerc, Stephen E. Sallan, Lewis B. Silverman, Daniel Sinnett, Thai Hoa Tran, Maja Krajinovic   +14 more
wiley   +1 more source